ArticleDisease markers2016
Galactose-Deficient IgA1 as a Candidate Urinary Polypeptide Marker of IgA Nephropathy?
Article in Disease markers, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
27 citing papers in PubMed, 2 syntheses or guidelines pooled it, 38 citations in OpenAlex.
- Examining the association between serum galactose-deficient IgA1 and primary IgA nephropathy: a systematic review and meta-analysis.Journal of nephrology · 2024Pooled it
- Diagnostic and prognostic value of galactose-deficient IgA1 in patients with IgA nephropathy: an updated systematic review with meta-analysis.Frontiers in immunology · 2023Pooled it
- Novel urinary glycan profiling by lectin array serves as the biomarkers for predicting renal prognosis in patients with IgA nephropathy.Scientific reports · 2021Trial
- Causal relationship between gut microbiota, circulating inflammatory proteins, and IgA nephropathy: two-sample and mediated Mendelian randomization analysis.International urology and nephrology · 2026Article
- Recent Advancements in the Therapeutic Landscape of IgA Nephropathy and the Impact of Dual Blockers: Telitacicept.Kidney medicine · 2026Review
- Machine learning-based diagnosis and prognosis of IgAN: A systematic review and meta-analysis.Heliyon · 2024Review
- Present and Future of IgA Nephropathy and Membranous Nephropathy Immune Monitoring: Insights from Molecular Studies.International journal of molecular sciences · 2023Review
- Serum levels of galactose-deficient IgA are elevated in patients with IgA nephropathy but do not correlate to disease activity or progression.BMC nephrology · 2023Article
- Role of abnormal glycosylated IgA1 and interstitial transformation of glomerular endothelial cells in the development and progression of IgA nephropathy.Italian journal of pediatrics · 2023Article
- Glomerular expression and urinary excretion of fatty acid-binding protein 4 in IgA nephropathy.Journal of nephrology · 2023Article
- Clinical Significance of the Intensity of Glomerular Galactose-Deficient IgA1 Deposition in IgA Nephropathy.Kidney international reports · 2022Article
- Mucosal Immune System Dysregulation in the Pathogenesis of IgA Nephropathy.Biomedicines · 2022Review
- Increased Urinary IgA in Paediatric IgA Vasculitis Nephritis.International journal of molecular sciences · 2022Article
- Galactose-Deficient IgA1 as a Candidate Urinary Marker of IgA Nephropathy.Journal of clinical medicine · 2022Article
- IgA Nephropathy with Gross Hematuria Following COVID-19 mRNA Vaccination.Internal medicine (Tokyo, Japan) · 2022Article
- IgA glycosylation and immune complex formation in IgAN.Seminars in immunopathology · 2021Review
- Current treatment of IgA nephropathy.Seminars in immunopathology · 2021Review
- IgA vasculitis nephritis in children and adults: one or different entities?Pediatric nephrology (Berlin, Germany) · 2021Review
- Leukemia Inhibitory Factor Signaling Enhances Production of Galactose-Deficient IgA1 in IgA Nephropathy.Kidney diseases (Basel, Switzerland) · 2020Article
- Monitoring Immune Responses in IgA Nephropathy: Biomarkers to Guide Management.Frontiers in immunology · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 4 institutions in 3 countries.
Funding
Abstract
In patients with IgA nephropathy (IgAN), circulatory IgA1 and IgA1 in mesangial deposits contain elevated amounts of galactose-deficient IgA1 (Gd-IgA1). We hypothesized that a fraction of Gd-IgA1 from the glomerular deposits and/or circulation may be excreted into the urine and thus represent a disease-specific biomarker. Levels of urinary IgA and Gd-IgA1 were determined in 207 patients with IgAN, 205 patients with other renal diseases, and 57 healthy controls, recruited in USA, Japan, and Italy. Urinary IgA was similarly elevated in patients with IgAN and renal-disease controls compared with healthy controls. However, urinary Gd-IgA1 levels were higher in patients with IgAN (IgAN, 28.0 ± 17.9; disease controls, 20.6 ± 17.4 units/mg urinary creatinine; P < 0.0001). Lectin western blotting data confirmed these results. In IgAN patients, levels of urinary Gd-IgA1 correlated with proteinuria (P < 0.001). When we purified IgA from serum and urine of an IgAN patient, the relative proportion of Gd-IgA1 to total IgA1 was higher in the urine compared with serum, suggesting selective excretion of Gd-IgA1 in IgAN. In summary, urinary excretion of Gd-IgA1 was elevated in patients with IgAN and the urinary Gd-IgA1 levels correlated with proteinuria. Urinary Gd-IgA1 may thus represent a disease-specific biomarker of IgAN.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.